Moody's Affirms Ratings of Mylan (MYL) Amid Meda Acquisition Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Mylan (MYL) Ratings Affirmed by Fitch Amid Meda Deal; Outlook Remains Stable
February 11, 2016 3:04 PM ESTFitch Ratings has affirmed the long-term Issuer Default Rating (IDR) of Mylan N.V. (Nasdaq: MYL), and the long-term ratings of its subsidiary Mylan, Inc., at 'BBB-' following the announcement that Mylan will acquire Meda A.B. (Meda) for approximately $9.9 billion. The Rating Outlook is Stable.
Mylan's ratings apply to approximately $7.3 billion of debt outstanding at Dec. 31, 2015. A full list of rating actions follows at the end of this release.
Fitch views the deal as strategically sound, strengthening Mylan's position in Western Europe while adding new important growth markets, including... More
Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal
February 11, 2016 11:09 AM ESTMylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More
Mylan to buy Swedish drugmaker Meda in $7.2 billion deal
February 10, 2016 4:49 PM ESTBy Natalie Grover
(Reuters) - Generic drugmaker Mylan NV (NASDAQ: MYL) said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.
The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (NYSE: PRGO).
Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts... More
